- Home
- PCRX vs DCOM Comparison
PCRX vs DCOM Comparison
Compare PCRX & DCOM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PCRX
- DCOM
- Stock Information
- Founded
- PCRX 2006
- DCOM 1864
- Country
- PCRX United States
- DCOM United States
- Employees
- PCRX N/A
- DCOM N/A
- Industry
- PCRX Biotechnology: Pharmaceutical Preparations
- DCOM Major Banks
- Sector
- PCRX Health Care
- DCOM Finance
- Exchange
- PCRX Nasdaq
- DCOM Nasdaq
- Market Cap
- PCRX 1.2B
- DCOM 1.2B
- IPO Year
- PCRX 2011
- DCOM 1996
- Fundamental
- Price
- PCRX $25.12
- DCOM $26.58
- Analyst Decision
- PCRX Buy
- DCOM Buy
- Analyst Count
- PCRX 9
- DCOM 4
- Target Price
- PCRX $29.89
- DCOM $33.88
- AVG Volume (30 Days)
- PCRX 782.0K
- DCOM 272.6K
- Earning Date
- PCRX 05-08-2025
- DCOM 04-22-2025
- Dividend Yield
- PCRX N/A
- DCOM 3.76%
- EPS Growth
- PCRX N/A
- DCOM N/A
- EPS
- PCRX N/A
- DCOM 0.62
- Revenue
- PCRX $702,772,000.00
- DCOM $295,419,000.00
- Revenue This Year
- PCRX $9.48
- DCOM $54.60
- Revenue Next Year
- PCRX $11.31
- DCOM $15.74
- P/E Ratio
- PCRX N/A
- DCOM $42.55
- Revenue Growth
- PCRX 3.08
- DCOM N/A
- 52 Week Low
- PCRX $11.16
- DCOM $17.49
- 52 Week High
- PCRX $31.67
- DCOM $37.60
- Technical
- Relative Strength Index (RSI)
- PCRX 48.10
- DCOM 53.12
- Support Level
- PCRX $25.08
- DCOM $25.92
- Resistance Level
- PCRX $27.34
- DCOM $26.92
- Average True Range (ATR)
- PCRX 1.16
- DCOM 0.80
- MACD
- PCRX -0.18
- DCOM 0.22
- Stochastic Oscillator
- PCRX 48.85
- DCOM 86.12
About PCRX Pacira BioSciences Inc.
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.
About DCOM Dime Community Bancshares Inc.
Dime Community Bancshares Inc operates as a holding company. It gathers deposits from customers within its market area and via the internet and invests them in multifamily residential, commercial real estate, commercial and industrial (C&I) loans, and one-to-four family residential real estate loans, as well as mortgage-backed securities, obligations of the U.S. government and government- sponsored enterprises (GSEs), and corporate debt and equity securities. The company has one reportable segment which is Community Banking.